{"id":"W2588916311","doi":"10.1056/nejmoa1613683","title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3390,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Janssen Pharmaceuticals; National Cancer Institute; Genentech; Cilag; Astellas Pharma; Sanofi; Exelixis; Eisai; BioClinica; Takeda Oncology; Amgen; Pfizer; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Hazard ratio; Internal medicine; Docetaxel; Chemotherapy; Oncology; Population; Gastroenterology; Urology; Cancer; Confidence interval; Surgery; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}